Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease
Maurizio Scarpa(Unknown), J. E. Wraith(Boston Children's Hospital), J Zeman(General University Hospital in Prague), Allan M. Lund(Copenhagen University Hospital), Anna Tylki‐Szymańska(Children's Memorial Health Institute), Nathalie Guffon(Hôpital Edouard Herriot), Iain Bruce(Royal Manchester Children's Hospital), Elisa Leão Teles(Hospital de São João), Zsuzsanna Almássy(Heim Pál Országos Gyermekgyógyászati Intézet), Bianca Link(University Children's Hospital Zurich), Simon Jones(Manchester University NHS Foundation Trust), Linda De Meırleır(Vrije Universiteit Brussel), Encarna Guillén‐Navarro(Hospital Universitario Virgen de la Arrixaca), Christoph Kampmann(Johannes Gutenberg University Mainz), Olaf A. Bodamer(Universitätsklinik für Kinder und Jugendpsychiatrie), Michael Beck(Eastern Illinois University), Robert Walker(Royal Manchester Children's Hospital), Christine Lavery(Amersham Hospital), Catherine Stewart(Birmingham Children's Hospital), Wolfgang Kamin(Johannes Gutenberg University Mainz), Christina Lampe(Johannes Gutenberg University Mainz), Michael Rothera(Royal Manchester Children's Hospital), Ans van der Ploeg(MRC Epidemiology Unit), Gunilla Malm(Karolinska University Hospital), Susanne Pitz(Johannes Gutenberg University Mainz), Pauline Hensman(Royal Manchester Children's Hospital)
Cited by 231
Related Papers
Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease
|New England Journal of Medicine|2019|808
Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy
|European Journal of Pediatrics|2007|522
Enzyme replacement therapy for mucopolysaccharidosis VI: A phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study
|The Journal of Pediatrics|2006|364
Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease
|Journal of Medical Genetics|2015|363
Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document
|Orphanet Journal of Rare Diseases|2015|345